Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Nat Rev Clin Oncol
; 18(8): 527-540, 2021 08.
Article
in En
| MEDLINE
| ID: mdl-33833434
ABSTRACT
Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate antitumour immunity owing to the inhibition of various immunosuppressive features of angiogenesis. Hence, combinations of anti-angiogenic agents and immunotherapy are currently being tested in >90 clinical trials and 5 such combinations have been approved by the FDA in the past few years. In this Perspective, we describe how the angiogenesis-induced endothelial immune cell barrier hampers antitumour immunity and the role of endothelial cell anergy as the vascular counterpart of immune checkpoints. We review the antitumour immunity-promoting effects of anti-angiogenic agents and provide an update on the current clinical successes achieved when these agents are combined with immune checkpoint inhibitors. Finally, we propose that anti-angiogenic agents are immunotherapies - and vice versa - and discuss future research priorities.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Clonal Anergy
/
Angiogenesis Inhibitors
/
Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Nat Rev Clin Oncol
Journal subject:
NEOPLASIAS
Year:
2021
Document type:
Article
Affiliation country: